Several brokerages have updated their recommendations and price targets on shares of Skye Bioscience (NASDAQ: SKYE) in the last few weeks:
- 9/20/2024 – Skye Bioscience had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $20.00 price target on the stock.
- 9/20/2024 – Skye Bioscience had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock.
- 9/10/2024 – Skye Bioscience is now covered by analysts at JMP Securities. They set an “outperform” rating and a $15.00 price target on the stock.
- 9/6/2024 – Skye Bioscience had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock.
- 8/27/2024 – Skye Bioscience had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock.
Skye Bioscience Trading Down 5.1 %
SKYE traded down $0.20 during midday trading on Friday, hitting $3.76. The company had a trading volume of 152,010 shares, compared to its average volume of 167,080. The stock’s 50 day moving average price is $5.58 and its 200 day moving average price is $5.98. Skye Bioscience, Inc. has a 52 week low of $1.44 and a 52 week high of $19.41.
Skye Bioscience (NASDAQ:SKYE – Get Free Report) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.20) EPS for the quarter, meeting analysts’ consensus estimates of ($0.20). Analysts predict that Skye Bioscience, Inc. will post -1.06 EPS for the current fiscal year.
Insider Activity
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new position in shares of Skye Bioscience during the 2nd quarter worth $30,000. Point72 DIFC Ltd purchased a new stake in Skye Bioscience during the second quarter valued at about $48,000. Rhumbline Advisers bought a new position in Skye Bioscience during the second quarter worth about $158,000. AdvisorShares Investments LLC purchased a new position in shares of Skye Bioscience in the second quarter worth about $210,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Skye Bioscience in the second quarter worth about $222,000. 21.09% of the stock is currently owned by hedge funds and other institutional investors.
Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
Further Reading
- Five stocks we like better than Skye Bioscience
- How to Start Investing in Real Estate
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Ride Out The Recession With These Dividend KingsĀ
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Skye Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Skye Bioscience Inc and related companies with MarketBeat.com's FREE daily email newsletter.